Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0F1ZI
|
|||
Former ID |
DIB007655
|
|||
Drug Name |
F-16-IL-2 fusion protein
|
|||
Synonyms |
Teleukin; F-16-IL-2; F-16-IL-2 fusion protein (cancer); F-16-IL-2 fusion protein (cancer), Philogen
Click to Show/Hide
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [1] | |
Company |
Philogen SpA
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Tenascin (TNC) | Target Info | Modulator | [2] |
KEGG Pathway | PI3K-Akt signaling pathway | |||
Focal adhesion | ||||
ECM-receptor interaction | ||||
MicroRNAs in cancer | ||||
NetPath Pathway | IL4 Signaling Pathway | |||
TGF_beta_Receptor Signaling Pathway | ||||
Pathway Interaction Database | Beta1 integrin cell surface interactions | |||
Beta3 integrin cell surface interactions | ||||
Alpha9 beta1 integrin signaling events | ||||
Syndecan-4-mediated signaling events | ||||
Reactome | Integrin cell surface interactions | |||
Syndecan interactions | ||||
ECM proteoglycans | ||||
WikiPathways | TGF beta Signaling Pathway | |||
Focal Adhesion | ||||
Syndecan interactions | ||||
Extracellular matrix organization | ||||
Integrin cell surface interactions |
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031837) | |||
REF 2 | National Cancer Institute Drug Dictionary (drug id 674718). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.